Shares of PAVmed (NASDAQ: PAVM) , a maker of tools for early detection of esophageal and pancreatic cancer, were down more than 15% as of 11:35 a.m. EDT today after the company reported earnings yesterday afternoon.
Image source: Getty Images.
For the six months ended June 30, the company posted a loss of $20 million. That was roughly equivalent to the same period last year. During that span, outstanding shares have increased 77%. Despite the dilution, the stock is still up nearly 200% so far this year.
For further details see:
Why Shares of PAVmed Were Down This Morning